On The Pen: The Weekly Dose
Dave Knapp brings you your weekly dose of everything in the news about incretin mimetic, diabetes and obesity therapies, like Zepbound and Mounjaro, Ozempic and Wegovy, and even investigational treatments like CagriSema and Retatrutide!
On The Pen: The Weekly Dose
On The Pen: The Weekly Dose 8.13.24
#ReleaseTheVials
https://www.onthepen.com/post/eli-lilly-to-releasethevials-of-zepbound
Eli Lilly has released single-dose vials for ZepBound to stabilize higher dose supplies and removed all Mounjaro and ZepBound doses from the FDA shortage list, though tirzepatide remains in shortage. Novo Nordisk is seeking FDA approval for Icosema, a combination of insulin and semaglutide, with a favorable safety profile.
Lilly Sends Tirzepatide Compound Cease and Desist Letters
https://www.onthepen.com/post/it-begins-eli-lilly-fires-off-round-of-cease-and-desist-letters-to-tirzepatide-peddlers
Eli Lilly is taking legal action against GLP-1 compounders, particularly targeting ZepBound. Cease and desist letters have been issued to smaller prescribers and med spas, potentially pressuring the FDA on tirzepatide’s shortage status.
#ReportTheShortage
Ro.co/supply-tracker
Patients are encouraged to report ZepBound or Mounjaro shortages to the FDA. Ro has introduced a supply tracker tool to notify patients of nearby availability and launched RoBody, a program connecting patients with doctors to manage obesity and achieve significant weight loss.
Insurance Checker Toll
Ro.co/checker
Ro's new GLP-1 Insurance Coverage Checker allows users to check insurance coverage for obesity medications and is integrated with the supply tracker. Despite financial struggles, 23andMe is launching a GLP-1 telehealth service. The ‘Opt-in for Obesity’ campaign encourages employees to request obesity coverage from their employers.
On The Pen Live
Z Reitano from Ro will discuss the GLP-1 Insurance Coverage Tool on the upcoming On The Pen Live session, airing on YouTube this Thursday at 9 p.m. Central.
#OptInForObesity
MY WORK RELIES ON YOUR GENEROSITY, WAYS TO SUPPORT:
Venmo: OnThePen
Ca$h App: ManOnMounjaro
BECOME A MEMBER:
https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/join
SOCIAL LINKS
https://www.tiktok.com/@manonthemounjaro
https://twitter.com/ManOnMounjaro
https://instagram.com/manonthemounjaro
https://facebook.com/manonthemounjaro
📲 Contact Me: MounjaroMan@gmail.com
📼 PLAYLISTS:
🖊️ ON THE PEN LIVES:
https://www.youtube.com/playlist?list=PLtOcNl0C8quVdrWruYSrJpTZPF7jjXKfM
👀 WATCH MY MOUNJARO JOURNEY IN ORDER:
https://www.youtube.com/watch?v=aplFxNOv77g&list=PLtOcNl0C8quWo7PWY9j_HilhWIRuedyiO
😎 NERDS ONLY: LEARN ABOUT OTHER GLP-1 MEDS:
https://www.youtube.com/playlist?list=PLtOcNl0C8quW-YZuu_DSpt_NS9fVQbMoW
🚨📰 ALL THE LATEST MOUNJARO NEWS:
https://www.youtube.com/playlist?list=PLtOcNl0C8quVo0I2YODK-q7cHh4y1r2yB
Thank you for tuning in! If you found this content valuable, make sure to like, share, and subscribe to my youtube channel for more updates on GLP-1, obesity, type 2 diabetes, and the latest news on Mounjaro, Zepbound, Wegovy, and Ozempic. Stay informed and entertained with my unique blend of breaking news, humor, and my personal journey. For in-depth articles and resources, visit my website at onthepen.com.
